ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness (how well the drug works), safety, and
tolerability of the investigational drug combination of ARRx (also known as AZD5312) plus
enzalutamide in patients with metastatic castration resistant prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center